Aktie SUCAMPO PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Sucampo Pharmaceuticals, Inc.

Aktien

US8649091068

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
SUCAMPO PHARMACEUTICALS, INC. Former SEC Attorney Willie Briscoe Investigates Sale to Mallinckrodt plc
Apple : POINT Marchés-Wall Street finit peu changée, freinée par Apple
Wall Street slips on tech sector weakness
Mallinckrodt : to buy Sucampo for about $840 million
Apple : Les valeurs à suivre à Wall Street
Alexion Pharmaceuticals : Les valeurs à suivre à Wall Street
Sucampo Pharmaceuticals : La biotech américaine Sucampo envisage de se vendre
Sucampo Pharmaceuticals Announces its Participation at the Global Mizuho Investor Conference
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 29th Annual Piper Jaffray Healthcare Conference
Sucampo to Host 2017 R&D Day on November 16 in New York
Sucampo Reports Third Quarter 2017 Financial Results
Sucampo Announces Third Quarter 2017 Earnings Call
Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
Sucampo Pharmaceuticals Announces Presentation at Deutsche Bank’s 25th Annual Leveraged Finance Conference
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel
Sucampo Pharmaceuticals : Cancer Prevention Pharmaceuticals Receives $9.5 Million in Additional Funding from Sucampo Following Phase 3 Trial Progress
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Wells Fargo Healthcare Conference
Sucampo Pharmaceuticals : Study Results Published in The Lancet Demonstrate Safety and Efficacy of Intrathecal VTS-270 in Niemann-Pick Disease Type C1
Sucampo Pharmaceuticals : Drug Makers Stock Performance Review -- DURECT, Sucampo Pharma, Apricus Biosciences, and MEI Pharma
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. Aktie
  4. Nachrichten Sucampo Pharmaceuticals, Inc.
  5. Andere Sprachen